Introduction: “Overlap syndrome (OS)” refers to patients with chronic obstructive pulmonary disease (referred to as COPD) with obstructive sleep apnea hypopnea syndrome (OSAHS). Patients with OSAHS have recurrent apnea and hypopnea during sleep, leading to hypoxemia. Patients with COPD have persistent airflow limitation and hypoxemia for a long time, which causes more severe hypoxia in OS patients. The coexistence of the two aggravates the patient’s condition, and is more likely to cause increased risk of hospitalization and mortality due to risk factors such as respiratory failure, heart failure, and arrhythmia. Objective: To study the M receptor blocker on inhalation in patients with overlap syndrome (chronic obstructive pulmonary disease and Obstructive sleep apnea syndrome) curative effect analysis. Methods: 25 patients with overlap syndrome as the experimental group, chronic obstructive pulmonary disease patients (30) as control group, patients with overlap syndrome use inhaled tiotropium powder treat 30 days, to observe the changes of pulmonary function, polysomnography, and other indicators after treatment. Results: Overlap syndrome were treated by tiotropium bromide inhalation powder, has improved the pulmonary function, the sleep apnea index and lowest nocturnal oxygen saturation after treatment. Conclusion: Tiotropium bromide has a preferable effective in treatment of overlap syndrome, COPD and OSAHS are interacting with each other.
Share this page on your timeline